HIV: Treating Patients with Viral Mutations

Opinion
Video

Sorana Segal-Maurer, MD, offers clinical insights on treating patients with HIV who have viral mutations, including M184V, highlighting guideline recommendations.

BIC = bictegravir

DRV = darunavir

DTG = dolutegravir

F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide

F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate

B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)

DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)

D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)

CAB = Cabotegravir

CAB + RPV = Cabotegravir + Rilpivirine

Video content above is prompted by the following questions:

  • Patients with viral mutations, including M184V, require a different and more tailored therapeutic approach to manage their disease.
    • Can you share your treatment approach for a patient with a viral mutation, such as M184V?
    • What are the current treatment guideline recommendation on this?

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.